INVESTOR RELATIONS

OVERVIEW

Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin's development pipeline includes a program in Huntington's disease and Myasthenia Gravis, two programs in Parkinson's disease, one in epilepsy, one in memory and a series of programs in cardiovascular disease.

Market Listings For Amarin Stock

Amarin is listed on the Nasdaq capital market (ticker: AMRN), with secondary listings on AIM in London (ticker: AMRN) and IEX in Dublin (ticker: H2E).  

INVESTOR RELATIONS

Recent News

more >>

Upcoming Events

more >>

There are currently no events scheduled

INVESTOR RELATIONS

Investor Relations Contacts

Amarin Corporation plc
First Floor, Block 3, The Oval
Ballsbridge, Dublin 4, Ireland

t: +353 (0) 1 669 9020
f: +353 (0) 1 669 9028
e: investor.relations@amarincorp.com

Lippert/Heilshorn & Associates Inc.
Anne Marie Fields

t: +1 212 838 3777
f: +1 212 838 4568

Media Contacts

Powerscourt
45 Ludgate Hill
EC4M 7JU
Rory Godson
Victoria Brough

t: +44 (0) 207 236 5615
f: +44 (0) 207 236 5702
e: info@powerscourtmedia.com